You just read:

Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer

News provided by

Amgen

May 29, 2015, 08:30 ET